

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GITREMDUR

Page 1 of 2

DOCTOR'S ORDERS Htcm Wt	_kg	BSA_	m²	
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form				
DATE: To be given:	Cycl	e #:		
Date of Previous Cycle:				
☐ Delay treatment week(s)				
May proceed with doses as written if within 96 hours ALT <u>less than or equal to</u> 3 times the upper limit of normal, total bilirubin <u>less than or equal to</u> 1.5 times the upper limit of normal, creatinine <u>less than or equal to</u> 1.5 times the upper limit of normal and <u>less than or equal to</u> 1.5 times baseline.				
Proceed with treatment based on blood work from				
PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm			·	
For prior infusion reaction to tremelimumab or durvalumab:				
diphenhydrAMINE 50 mg PO 30 minutes prior to treatment				
acetaminophen 325 to 975 mg PO 30 minutes prior to treatment				
hydrocortisone 25 mg IV 30 minutes prior to treatment				
Have Hypersensitivity Reaction Tray & Protocol Available				
TREATMENT:				
☐ Cycle 1:				
Vital signs immediately before the start of tremelimumab infusion, at 30 minutes in as needed	ito the	infusi	on, at end of infusion, and	
tremelimumab 300 mg IV in 50 mL NS over 60 minutes using a 0.2 micron in-line filter*				
durvalumab 20 mg/kg xkg = mg (max. 1500 mg) IV in 100 mL NS over 60 minutes using a 0.2 micron in-line filter*				
* Use separate infusion line and filter for each drug				
Patients to be observed for one hour from end of durvalumab infusion.				
☐ Cycles 2 onwards:				
durvalumab 20 mg/kg xkg = mg (max. 1500 mg) every 4 we IV in 100 mL NS over 60 minutes using a 0.2 micron in-line filter	eks			
No observation required if no prior infusion-related reaction to durvalumab				
Continued on page 2				
DOCTOR'S SIGNATURE:			SIGNATURE:	
			UC:	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GITREMDUR

Page 2 of 2

DATE:				
☐ Cycle				
One time only, Cycle 5 or later. For one-time tremelimumab retreatment with durvalumab.				
Maximum 2 doses tremelimumab per patient.				
tremelimumab 300 mg				
IV in 50 mL NS over 60 minutes using a 0.2 micron in-line filter*				
durvalumab 20 mg/kg x kg = mg (max. 1500 mg)				
IV in 100 mL NS over 60 minutes using a 0.2 micron in-line filter*				
* Use separate infusion line and filter for each drug				
Vital signs immediately before the start of tremelimumab infusion, at 30 minutes into the infusion, at end of infusion, and as needed				
No observation required if no prior infusion-related reaction to tremelimumab or durvalumab				
RETURN APPOINTMENT ORDERS				
Return in four weeks for Doctor and Cycle #				
Last cycle. Return in week(s).				
CBC & Diff, platelets, creatinine, sodium, potassium, total bilirubin, ALT, INR, TSH prior to				
each treatment				
If clinically indicated:				
☐ ECG ☐ chest x-ray ☐ AFP				
☐ serum hCG or ☐ urine hCG – required for woman of childbearing potential				
☐ free T3 and free T4 ☐ lipase ☐ morning serum cortisol				
☐ serum ACTH levels ☐ testosterone ☐ estradiol ☐ FSH ☐ LH				
☐ random glucose ☐ alkaline phosphatase ☐ albumin				
☐ creatine kinase ☐ troponin				
☐ Weekly nursing assessment				
Other consults:				
See general orders sheet for additional requests.				
DOCTOR'S SIGNATURE:	SIGNATURE:			
	UC:			